Takeda Pharmaceutical (TAK) Non-Current Deferred Tax Liability: 2018-2025

  • Takeda Pharmaceutical's Non-Current Deferred Tax Liability fell 69.99% to $230.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $230.4 million, marking a year-over-year decrease of 69.99%. This contributed to the annual value of $230.8 million for FY2025, which is 70.75% down from last year.
  • According to the latest figures from Q1 2025, Takeda Pharmaceutical's Non-Current Deferred Tax Liability is $230.4 million, which was down 69.99% from $767.7 million recorded in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Non-Current Deferred Tax Liability peaked at $5.1 billion during Q1 2021, and registered a low of $230.4 million during Q1 2025.
  • Over the past 3 years, Takeda Pharmaceutical's median Non-Current Deferred Tax Liability value was $767.7 million (recorded in 2024), while the average stood at $1.0 billion.
  • Data for Takeda Pharmaceutical's Non-Current Deferred Tax Liability shows a maximum YoY plummeted of 69.99% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Takeda Pharmaceutical's Non-Current Deferred Tax Liability stood at $5.1 billion in 2021, then declined by 24.24% to $3.9 billion in 2022, then slumped by 47.34% to $2.0 billion in 2023, then crashed by 62.47% to $767.7 million in 2024, then slumped by 69.99% to $230.4 million in 2025.
  • Its Non-Current Deferred Tax Liability stands at $230.4 million for Q1 2025, versus $767.7 million for Q1 2024 and $2.0 billion for Q1 2023.